Intro -- Acknowledgements -- Abbreviations -- Glossary -- 1. Introduction -- 2. Seasonal malaria chemoprevention -- 2.1 What is SMC? -- 2.2 Who is eligible for SMC? -- 2.3 Where should SMC be implemented? -- 2.4 When should SMC be implemented? -- 2.5 Why is SP+AQ recommended? -- 2.5.1 Dosing schedules for SP+AQ -- 2.5.2 Contraindications -- 2.6 Chemoprevention efficacy and drug resistance -- 2.7 Safety -- 2.8 Expected benefits of SMC -- 2.9 Considerations for deployment of SMC -- 2.10 Costs and cost-effectiveness of SMC -- 3. Updating of national SMC policy -- 3.1 Situation analysis -- 3.1.1 Context -- 3.1.2 Malaria situation -- 3.1.3 Health system situation -- 3.2 Data to guide decisions on number of SMC cycles per district -- 3.3 Data to guide age range expansion -- 3.4 Data to guide spatial targeting -- 3.5 Policy update or development process -- 4. Planning and implementation -- 4.1 Distribution strategies -- 4.1.1 Door-to-door distribution -- 4.1.2 Fixed-point distribution -- 4.1.3 Mixed SMC delivery models -- 4.1.4 Delivering SMC in insecure areas -- 4.1.5 Payment strategies for SMC campaign workers -- 4.2 Preparing an SMC implementation plan -- 4.2.1 Key activities of SMC planning -- 4.2.2 Training SMC campaign staff (cascade training) -- 4.2.3 Social mobilization and communication -- 4.2.4 Supply chain management -- 4.3 SMC implementation -- 4.3.1 Supervision -- 4.3.2 Algorithm for administering SP+AQ -- 4.3.3 Absence of a child during the SMC cycle -- 4.3.4 Combining SMC with other interventions -- 4.3.5 Cross-border collaboration -- 4.4 Roles and responsibilities at various levels -- 4.4.1 National level -- 4.4.2 Regional level -- Activities: -- 4.4.3 District level -- 4.4.4 Peripheral health facility level -- 4.4.5 Community level -- 5. Monitoring and evaluation -- 5.1 Performance framework -- 5.1.1 Indicators.

5.1.2 Data sources and data collection methods -- 5.1.3 Digitizing the SMC campaign -- 5.1.4 Known challenges with monitoring SMC coverage -- 5.2 Monitoring adverse drug reactions -- 5.2.1 Definitions -- 5.2.2 Recording and reporting adverse events -- 5.2.3 Potential difficulties in reporting adverse events -- 5.3 Monitoring and reporting of costs -- 5.4 Final end-of-campaign report -- References.